Repeated exposure to TLR2 agonists may exacerbate neurodegeneration in AD by their microglial-mediated toxicity (Lax et al., 2020) and inhibition of TLR2 in microglia (Liu et al., 2012) or mouse model could be beneficial in AD pathogenesis. The gene discussed is TLR2; the disease is Alzheimer disease.